Our Work

VVT Medical Inc.

Principals at I3 Capital advised ExitTeam Acquisition Corporation on it’s acquisition of VVT Medical in furtherance of a Reverse Takeover on the TSX Venture Exchange
VVT is a manufacturer of varicose vein treatment devices that have completed 3,800+ procedures with no reported pain or complications. Approved for use in the USA, EU, India, Australia, Korea and the UAE. $30MM in distribution agreements over 5 years.
VVTM:TSXV
www.vvtmed.com

Learn More >
GreenData Centers Inc

Principals at I3 Capital are advising the senior leadership team at GreenData Centers including raising equity & debt capital for it’s initial property site acquisition and subsequent transactions with Hyperscaler clients
Pursuing listing on NASDAQ
www.greendatacenters.com
NurExone Biologic

I3 Capital and Foundation Markets Inc are advising the company (TSXV: NRX) and are a joint book runner for the company’s new equity offering.
NRX:TSXV
www.nurexone.com

I3 Capital

Toronto | Miami | Tel Aviv

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. I3 Capital is not a registered broker-dealer, and Finalis Securities LLC and I3 Capital Group Ltd. are separate, unaffiliated entities.

Finalis Privacy Policy | Finalis Business Continuity Plan |FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)

www.i3-capital.com (the “I3 Capital Website”) is a website operated by I3 Capital Group Ltd.. This website is for informational purposes only; it is not an offer, solicitation, recommendation, or commitment to engage in any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available to residents of certain jurisdictions. Please consult with a Finalis Securities registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and [Insert DBA Name] along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.

Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.

Content on this web site and other I3-branded online content including blogs and social media posts should not be construed as investment advice. I3-Capital receives fees from all companies listed under the “Clients” section of this web site for various services which include any or all of capital markets advisory, investor relations, media advisory and independent editorial content. The opinions expressed in such editorial articles are solely those of the individual writer. Any reliance on the content of these articles is at your sole risk. You should not make any investment decision regarding any content published by I3 Capital without first obtaining advice from a registered investment advisor or other qualified professional.

VVT Medical Inc.

GreenData Centers Inc

NurExone Biologic

I3 Capital